59 / 88
59
Wednesday, 21 June 2017
/ Scientific Programme
WFSBP 2017
WED
003
The WFSBP Treatment guideline for mixed states-
evidence and recommendations
Heinz Grunze, United Kingdom
004
What the CINP guideline recommends in mixed
states
Konstantinos Fountoulakis, Greece
T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)
S-51
SYMPOSIUM
15:00–16:30
Auditorium 15
Advances in biomarker development for neuro-
stimulation
Chair:
Paul Croarkin, USA
Co-Chair: Motoaki Nakamura, Japan
001
Stimulation-induced neuroplasticity of prefrontal
cortex in adult autism spectrum disorder
Motoaki Nakamura, Japan
002
Glutamatergic biomarker development for repeti-
tive transcranial magnetic stimulation
Paul Croarkin, USA
003
Neurocognitive effects of major depressive disor-
der and neurostimulation therapies
Shawn McClintock, USA
004
Predicting remission of suicidal ideation following
Magnetic Seizure Therapy (MST) in patients with treat-
ment-resistant depression
Zafiris J. Daskalakis, Canada
T3: ANTIPSYCHOTICS: BASIC/ CLINICAL
S-52
SYMPOSIUM
15:00–16:30
Auditorium 10
The G protein coupled receptors as a target for
psychotropic drugs
Chair:
Andrzej Pilc, Poland
Co-Chair: Jeffrey P. Conn, USA
001
Positive allosteric modulators of GPCRs as a novel
treatment for schizophrenia
Jeffrey P. Conn, USA
002
The mGlu5 receptor imaging in schizophrenia and
depression
Gregor Hasler, Switzerland
003
The mGlu2 / 3 receptor as a novel therapeutic
target for treatment-resistant depression
Shigeyuki Chaki, Japan
004
The allosteric modulation of group III mGlu recep-
tors as target for antipsychotic or antidepressant drugs
Andrzej Pilc, Poland
T49: SUICIDE: BASIC/ CLINICAL
S-53
SYMPOSIUM
15:00–16:30
B3 M3-M4
Suicidal behavior: Neurobiological and genetic
determinants
Chair:
Yogesh Dwivedi, USA
001
Epigenetic modifications in brain of suicide indi-
viduals: Focus on global and site-specific changes in
5-hydroxymethylcytosine
Gustavo Turecki, Canada
002
Genetics of intermediate phenotypes for suicidal
behavior: Focus on impulsivity and aggression
Dan Rujescu, Germany
003
Toxoplasmagondii seropositivity and suicidal
behavior
Teodor Postalache, USA
004
Non-coding RNAs: Novel epigenetic regulators in
suicidal behavior
Yogesh Dwivedi, USA
T23: MOOD STABILISERS: BASIC/ CLINICAL
S-55
SYMPOSIUM
15:00–16:30
Auditorium 11
Rediscovering Lithium
Chair:
David Taylor, United Kingdom
Co-Chair: Jonathan Meyer, USA
001
The evidence for Lithium's antisuicide properties
and impact on mortality
Jimmi Nielsen, Denmark
002
The evidence for Lithium's neuroprotective
properties
Barrat Luft, United Kingdom
003
What is the risk for end stage renal disease with
Lithium: A sophisticated review
Ursula Werneke, Sweden
M. Ott, E. Salander Renberg, B. Stegmayr
004
An update on assessing and managing Lithium's
renal effects
Jonathan Meyer, USA